Psychology Writing Services

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs?

PHI FPX 3200 Assessment 2 A Right to Experimental Drugs? Free Sample Papers Anxiety (1) BS Psychology (42) Depression (11) Essay (2) Need writer for your Psychology Papers? Get your paper in 24 Hours. We have a team of Psychology Academic Writers who can help you quickly write plagiarism-free papers, essays, and research articles. Hire Writer PHI FPX 3200 Assessment 2 A Right to Experimental Drugs? Name Capella University PHI FPX 3200 Ethics in Health Care Prof. Name Date A Right to Experimental Drugs The discourse surrounding the provision of experimental drugs sparks fervent debate among advocates and critics alike. Proponents argue that access to experimental treatments offers hope for patients who have exhausted conventional options, potentially leading to recovery (Bunnik & Aarts, 2019). However, critics raise valid concerns regarding safety, efficacy, and ethical implications, highlighting the need for thorough examination (Bunnik & Aarts, 2019). Central to this discourse is the concept of informed consent, which necessitates patients’ understanding of the risks, benefits, and uncertainties associated with experimental treatments (Dankar et al., 2019). Regulatory bodies such as the FDA play a crucial role in evaluating the safety and efficacy of these treatments, though opinions vary on the balance between caution and access (FDA, 2019). Ethical Theories and Moral Principles Ethical theories and moral principles serve as guiding frameworks in healthcare decision-making. Utilitarianism, deontological ethics, and virtue ethics, along with principles such as autonomy and beneficence, shape responses to healthcare dilemmas (Vearrier & Henderson, 2021). In the context of experimental drugs, these frameworks inform considerations of risk, patient autonomy, and compassionate decision-making (Tseng & Wang, 2021). Integrating these theories and principles is essential for navigating complex healthcare challenges and ensuring ethical decision-making (Mathúna et al., 2020). Principle of Informed Consent Informed consent holds significant importance in the realm of experimental drugs, given their investigational nature. Patients participating in clinical trials must be fully informed about potential risks, benefits, and alternatives (Dankar et al., 2019). This includes understanding the nature of the drug, potential side effects, and the voluntary nature of participation (Varkey, 2021). Informed consent upholds patient autonomy and facilitates ethically sound decision-making in medical research (Dankar et al., 2019). Assumptions Informed consent in experimental drug trials relies on several assumptions, including respect for autonomy, comprehensive information disclosure, and voluntary participation. These assumptions underpin ethical principles and ensure that patients are empowered to make informed choices about their health. Costs and Benefits of Unapproved Experimental Drugs The debate over providing unapproved experimental drugs to patients involves weighing potential benefits against inherent risks (Feustel et al., 2019). While proponents argue for increased access and innovation, critics emphasize safety concerns and the need for rigorous testing (Feustel et al., 2019). Ethical considerations, including risk-benefit assessment and informed consent, underscore the complexity of this issue (Madeddu et al., 2021). Pre-approved Drug Usage for a Wider Patient Pool Expanding the use of pre-approved drugs raises ethical considerations regarding patient autonomy and healthcare resource allocation (White, 2022). Proponents highlight potential benefits for patient outcomes, while opponents caution against over-medication and advocate for individualized treatment approaches (Heydari et al., 2020). Knowledge Gaps and Missing Information Addressing knowledge gaps is essential for informed decision-making regarding unapproved drugs. Research must explore safety, efficacy, and ethical implications, particularly concerning long-term effects and vulnerable patient populations (Cohen et al., 2020). Conclusion In conclusion, the debate surrounding the right to experimental drugs necessitates careful consideration of ethical principles and moral frameworks. While these drugs hold promise, their use entails significant risks and ethical dilemmas. Striking a balance between access and safety is crucial, with regulatory oversight ensuring adherence to ethical standards. Ultimately, decisions must prioritize patient welfare, guided by thorough risk-benefit assessments and ethical considerations. References Amrutkar, S. S., Patil, S. B., & Mundada, A. S. (2022). Abbreviated new drug submission approval process: An overview. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 174113432211460. https://doi.org/10.1177/17411343221146094 Bendicksen, L., Kesselheim, A. S., & Rome, B. N. (2022). The vexing voyage of vasopressin. Chest, 162(2), 433–435. https://doi.org/10.1016/j.chest.2022.02.048 Borysowski, J., & Górski, A. (2019). Compassionate use of unauthorized drugs: Legal regulations and ethical challenges. European Journal of Internal Medicine, 65, 12–16. https://doi.org/10.1016/j.ejim.2019.04.008 Bunnik, E. M., & Aarts, N. (2019). What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. BMC Medical Ethics, 20(1). https://doi.org/10.1186/s12910-019-0420-8 Cohen, P. A., Avula, B., Wang, Y. H., Zakharevich, I., & Khan, I. (2020). Five unapproved drugs found in cognitive enhancement supplements. Neurology: Clinical Practice. https://doi.org/10.1212/CPJ.0000000000000960 Dankar, F. K., Gergely, M., & Dankar, S. K. (2019). Informed consent in biomedical research. Computational and Structural Biotechnology Journal, 17, 463–474. https://doi.org/10.1016/j.csbj.2019.03.010 FDA. (2019). Drugs. Fda.gov. https://www.fda.gov/drugs Feustel, A. C., MacPherson, A., Fergusson, D. A., Kieburtz, K., & Kimmelman, J. (2019). Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology, 94(1), e1–e14. https://doi.org/10.1212/wnl.0000000000008699 Heydari, M., Mehraeen, M., & Joulaei, H. (2020). Overmedication and waste of resources in physicians’ prescriptions: A cross-sectional study in southwestern Iran. Shiraz E-Medical Journal, 21(9). https://doi.org/10.5812/semj.97662 Madeddu, C., Neri, M., Sanna, E., Oppi, S., & Macciò, A. (2021). Experimental drugs for chemotherapy- and cancer-related anemia. Journal of Experimental Pharmacology, Volume 13, 593–611. https://doi.org/10.2147/jep.s262349 PHI FPX 3200 Assessment 2 A Right to Experimental Drugs? Nandifa, V. N. P., Jena, Y., & Joewana, S. (2020). Beneficence is the highest moral imperative of a doctor dealing with the poor quality of patient autonomy. Jurnal Pendidikan Kedokteran Indonesia: The Indonesian Journal of Medical Education, 9(1), 44. https://doi.org/10.22146/jpki.44511 O’Mathúna, D. P., Escartín, C. P., Roche, P., & Marlowe, J. (2020). Engaging citizen translators in disasters. Translation and Interpreting Studies. https://doi.org/10.1075/tis.20003.oma Quaranta, A., D’Isidoro, O., Piattelli, A., Hui, W. L., & Perrotti, V. (2022). Illegal drugs and periodontal conditions. Periodontology 2000, 90(1), 62–87. https://doi.org/10.1111/prd.12450 Tseng, P.-E., & Wang, Y.-H. (2021). Deontological or utilitarian? An eternal ethical dilemma in outbreak. International Journal of Environmental Research and Public Health, 18(16), 8565. https://doi.org/10.3390/ijerph18168565 Varkey, B. (2021). Principles of clinical ethics and their application to practice. Medical Principles and Practice, 30(1), 17–28. https://doi.org/10.1159/000509119 Vearrier, L., & Henderson, C. M. (2021). Utilitarian principlism as a framework for crisis

Get In Touch

    Psychology Writing Services delivers tailored solutions for academic and professional exploration of the human psyche.

    Our Services

    our services

    © Copyright 2024 powered by PsychologyWritingServices.com

    You cannot copy content of this page, Contact Team if you need Help